Derakhshan Behrad 4
4 · Edgewise Therapeutics, Inc. · Filed Sep 24, 2024
Insider Transaction Report
Form 4
Derakhshan Behrad
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2024-09-20$1.93/sh+42,068$81,191→ 57,189 total - Sale
Common Stock
2024-09-20$29.03/sh−42,068$1,221,133→ 15,121 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-09-20−42,068→ 102,949 totalExercise: $1.93Exp: 2030-12-15→ Common Stock (4,763 underlying)
Footnotes (3)
- [F1]Includes 1,699 shares purchased on May 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
- [F2]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.28, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date.